BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia - PubMed (original) (raw)
BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia
Hongfeng Yuan et al. J Biol Chem. 2010.
Abstract
Acquired resistance through genetic mutations is a common phenomenon in several cancer therapies using molecularly targeted drugs, best exemplified by the BCR-ABL inhibitor imatinib in treating chronic myelogenous leukemia (CML). Overcoming acquired resistance is a daunting therapeutic challenge, and little is known about how these mutations evolve. To facilitate understanding the resistance mechanisms, we developed a novel culture model for CML acquired resistance in which the CML cell line KCL-22, following initial response to imatinib, develops resistant T315I BCR-ABL mutation. We demonstrate that the emergence of BCR-ABL mutations do not require pre-existing BCR-ABL mutations derived from the original patient as the subclones of KCL-22 cells can form various BCR-ABL mutations upon imatinib treatment. BCR-ABL mutation rates vary from cell clone to clone and passages, in contrast to the relatively stable mutation rate of the hypoxanthine-guanine phosphoribosyltransferase gene. Strikingly, development of BCR-ABL mutations depends on its gene expression because BCR-ABL knockdown completely blocks KCL-22 cell relapse on imatinib and acquisition of mutations. We further show that the endogenous BCR-ABL locus has significantly higher mutagenesis potential than the transduced randomly integrated BCR-ABL cDNA. Our study suggests important roles of BCR-ABL gene expression and its native chromosomal locus for acquisition of BCR-ABL mutations and provides a new tool for further studying resistance mechanisms.
Figures
FIGURE 1.
Novel model of CML acquired resistance. A, one-half million KCL-22 cells were treated with 1, 2.5, 5, and 10 μ
m
imatinib (STI), and at days after the treatment as indicated, survival cells were counted. Relapse occurred on 2.5 μ
m
and higher concentrations of imatinib 2 weeks post-treatment. B, top, apoptosis of KCL-22 cells after 6 days of treatment with 5 μ
m
imatinib was analyzed by annexin V staining. DAPI, 4′,6-diamidino-2-phenylindole. Bottom, formation of clusters of resistant cells (bright) among scattered dead cells (dark) with 2.5 μ
m
STI-571 treatment for 8 days. C, top, growth curves for resistant cells (KCL-22M) and KCL-22 cells analyzed by XTT. Growth indexes were relative XTT readings normalized to the initial XTT readings at day 0. Bottom, comparison of growth of KCL-22M cells in the absence and presence of imatinib. D, soft agar colony formation of KCL-22 and KCL-22M cells. Five hundred cells were seeded each well in 6-well plates in triplicate. E, comparison of cell size and complexity of KCL-22 and KCL-22M cells. KCL-22M cells exhibited increase at both forward scatter (FS) and side scatter (SC) parameters. SS Lin, side scatter in linear scale. F, comparison of cell cycle of KCL-22 and KCL-22M cells with propidium iodine staining.
FIGURE 2.
Cytogenetic characteristics of KCL-22M cells. A, karyogram of 24-color spectral karyotyping. The composite karyotype is 51,X,del(X)(p11.2p22.3),+der(1;10)(q10;p10),+6,+8,+8,t(9;22) (q34.1;q11.2),der(17;19)(q10;q1),+19,i(21)(q10),+der(22)t(9;22)[10]. B, left, representative three-color FISH of BCR-ABL. Two Philadelphia chromosomes (9/22) were present in all cells. Right, the color code for FISH probes. ASS, argininosuccinate synthetase gene.
FIGURE 3.
Molecular characterizations of the new CML resistance model. A, left, Western blot analysis of BCR-ABL expression and tyrosine phosphorylation in KCL-22 and KCL-22M cells with and without imatinib treatment. The top band (arrow) detected by the tyrosine phosphorylation antibody corresponds to the position of BCR-ABL. Right, immunoprecipitation of KCL-22 cell lysate with BCR-ABL antibody or normal IgG followed by Western analysis for BCR-ABL expression and phosphorylation. P-Tyr, phosphotyrosine; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. B, sequencing analysis of BCR-ABL kinase domain with cDNA or genomic DNA from KCL-22 and KCL-22M cells. Notice the point mutation of C to T (in bold and red) that causes T315I amino acid change. C, sequencing of BCR-ABL kinase domain mutations in clonal cells. KCL-22M cells derived from 2.5 and 5 μ
m
imatinib treatment were subcloned by limiting dilution, and 10 clones each (liquid culture clones) were sequenced using genomic templates. Clonal cells were separately obtained by plating KCL-22 cells on soft agar with 2.5 or 5 μ
m
imatinib, and 10 colonies each were sequenced. D, mutation frequencies of KCL-22 cells. One million KCL-22 cells were seeded on soft agar with the indicated concentrations of imatinib, and resistant colonies were scored after 3 weeks. E, mutation detection by conventional DNA sequencing. KCL-22 cells cultured without or with 1 μ
m
imatinib for 2 weeks were analyzed. Forty one bacterial clones for untreated cells and 12 for treated cells were sequenced. Mutations were found in only two clones in the latter.
FIGURE 4.
Acquired resistance of clonal CML cells on imatinib treatment. A, time courses of relapse for four KCL-22 clones as analyzed in Fig. 1_A_. Notice that clones L1 and Ag 11 relapsed on imatinib with time courses similar to parental cells, but clones L7 and Ag3 relapsed with slower time courses. B, resistance of recurrent clonal cells to higher concentrations of imatinib. Recurrent cells derived from 2.5 μ
m
imatinib treatment for four clones were labeled with clone names followed by 2.5R. All recurrent cells were maintained in the medium without imatinib until analysis. Notice the different levels of resistance of L1–2.5R (E255K mutation), L7–2.5R (Y253H mutation), and Ag11–2.5R (T315I mutation) to the higher concentrations of imatinib. Growth of Ag3–2.5R (no mutation) was inhibited by 5 μ
m
imatinib. C, cells from clones L1 and Ag11 were plated on soft agar with 2.5 μ
m
imatinib for 3 weeks, and 10 colonies each were picked for sequencing analysis of BCR-ABL kinase domain mutations. D, mutations from mixed clonal cells. Equal numbers of eight never-relapsed clones were mixed to form a nonrelapse pool (N-pool). Clone L1, L7, or Ag3 was then mixed 1:1 with a nonrelapse pool for resistance analysis in liquid culture, and recurrent cells were analyzed for BCR-ABL mutations.
FIGURE 5.
Comparison of BCR-ABL mutations with spontaneous HPRT mutations. A, measurement of BCR-ABL and HPRT mutation rates. One million cells of each clone were plated on soft agar with 2.5 μ
m
imatinib (STI) or 2.5 μg/ml 6-thioguanine (6-TG) for side-by-side analysis of BCR-ABL and HPRT mutation frequencies, respectively. B, left, BCR-ABL and HPRT mutation rates of KCL-22 cells at passages 5, 16, and 36 measured by soft agar clonogenic assay. Imatinib, 5 μ
m
; 6-thioguanine, 2.5 μg/ml. Right, time courses for relapse of KCL-22 cells on 2.5 μ
m
imatinib at passages 8 and 35. Relapsed cells harbored T315I mutation in both cases. C, HPRT mutation spectrum. Ag11, L1, or KCL-22 cells were seeded on soft agar with 6-thioguanine, and 20 colonies each were picked for analysis of HPRT codon mutations. For Ag11, two colonies had sequencing failure and were excluded.
FIGURE 6.
ROS and DNA damage in KCL-22 cells upon imatinib treatment. A, analysis of ROS in different apoptotic fractions of KCL-22 cells treated with 2.5 μ
m
imatinib for 4 days. ROS increased in all apoptotic fractions of the cells with early apoptotic cells (top left square) having the highest level. Nonapoptotic fraction of the cells (bottom left square) had the lowest level of ROS. DAPI, 4′,6-diamidino-2-phenylindole. B, bulk ROS level decreased in nonapoptotic fraction of KCL-22 cells that were treated with 2.5 μ
m
imatinib for 2 days. Similar results were seen for 1 day of drug treatment (not shown). C, bulk γH2AX level decreased in KCL-22 cells treated with 2.5 μ
m
imatinib for 2 days. D, treatment with anti-oxidants. No effects of NAC or vitamin E were seen to prevent or delay KCL-22 cells from relapse on 2.5 μ
m
imatinib except for 50 m
m
NAC that itself has significant cytotoxicity (data not shown).
FIGURE 7.
Induction of BCR-ABL mutations is dependent on BCR-ABL expression. A, top, analysis of apoptosis of KCL-22 and KCL-22M cells 6 days after BCR-ABL knockdown. Scrambled shRNA was used for mock knockdown. Less apoptotic cells were noticed in KCL-22M. Bottom, BCR-ABL protein levels after knockdown. DAPI, 4′,6-diamidino-2-phenylindole; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. B, top, effects of BCR-ABL knockdown on acquired resistance on imatinib. After the knockdown, cells regrew, and they were selected for 5 days in puromycin and expanded in drug-free medium. These re-grown BCR-ABL knockdown KCL-22 cells and mock knockdown cells were treated with 5 μ
m
imatinib, and cells were followed as described in Fig. 1. Bottom, BCR-ABL levels in the re-grown knockdown cells. C, effects of BCR-ABL knockdown on formation of imatinib-resistant colonies on soft agar. The re-grown BCR-ABL knockdown (shABL) or mock knockdown KCL-22 cells were plated on soft agar with 5 μ
m
imatinib. The plating efficiency for mock and ABL knockdown was the same (data not shown). D, effects of combining BCR-ABL knockdown with imatinib treatment on acquired resistance. Cells were transduced overnight with lentiviral vectors, and imatinib was added right after the removal of viruses.
FIGURE 8.
Effects of BCR-ABL overexpression on mutations. A, analysis of BCR-ABL expression and total cellular phosphorylation. KCL-22 cells were transduced with empty vector (R1), wild type p210 BCR-ABL (WT), or kinase-inactive p210 mutant (KI). Lysates were collected without or with 2.5 and 5 μ
m
imatinib treatment. B, clonogenic assay of BCR-ABL-overexpressing cells for imatinib resistance with 1,000,000 cells plated each well in triplicate. Imatinib-resistant colonies were plucked and expanded for genomic sequencing of the endogenous BCR-ABL (BA) kinase domain. The number of colonies found with T315I mutation over the total number of colonies sequenced are listed below each category of graph bars. C, analysis of the transduced BCR-ABL cDNA in imatinib-resistant colonies overexpressing wild type BCR-ABL by PCR amplification of 579- and 321-bp fragments of BCR-ABL cDNA from genomic templates using exon primers. Both 579- and 321-bp fragments were sequenced. Only one colony, clone 5 from 2.5 μ
m
imatinib treatment group marked by an asterisk, had BCR-ABL mutation (T315I). Colonies with T315I mutation of the endogenous BCR-ABL were as follows: clones 1, 2, 4, 5, 7, 8, and 10 from 5 μ
m
imatinib group, and clones 1 and 7 from 2.5 μ
m
imatinib group.
Similar articles
- Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
Yuan H, Wang Z, Zhang H, Roth M, Bhatia R, Chen WY. Yuan H, et al. Carcinogenesis. 2012 Feb;33(2):285-93. doi: 10.1093/carcin/bgr278. Epub 2011 Nov 24. Carcinogenesis. 2012. PMID: 22116466 Free PMC article. - Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
Lu Z, Jin Y, Chen C, Li J, Cao Q, Pan J. Lu Z, et al. Mol Cancer. 2010 May 19;9:112. doi: 10.1186/1476-4598-9-112. Mol Cancer. 2010. PMID: 20482842 Free PMC article. - HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS. Yun SM, et al. Cancer Lett. 2014 Jun 28;348(1-2):50-60. doi: 10.1016/j.canlet.2014.03.012. Epub 2014 Mar 18. Cancer Lett. 2014. PMID: 24657654 - Overcoming kinase resistance in chronic myeloid leukemia.
Lee F, Fandi A, Voi M. Lee F, et al. Int J Biochem Cell Biol. 2008;40(3):334-43. doi: 10.1016/j.biocel.2007.10.001. Int J Biochem Cell Biol. 2008. PMID: 18401881 Review. - Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
Nardi V, Azam M, Daley GQ. Nardi V, et al. Curr Opin Hematol. 2004 Jan;11(1):35-43. doi: 10.1097/00062752-200401000-00006. Curr Opin Hematol. 2004. PMID: 14676625 Review.
Cited by
- Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition.
Bütow M, Testaquadra FJ, Baumeister J, Maié T, Chatain N, Jaquet T, Tillmann S, Crysandt M, Costa IG, Brümmendorf TH, Schemionek M. Bütow M, et al. Haematologica. 2023 Apr 1;108(4):1179-1185. doi: 10.3324/haematol.2022.280922. Haematologica. 2023. PMID: 36453102 Free PMC article. No abstract available. - BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia.
Parry N, Busch C, Aßmann V, Cassels J, Hair A, Helgason GV, Wheadon H, Copland M. Parry N, et al. Cell Death Discov. 2022 Nov 15;8(1):457. doi: 10.1038/s41420-022-01211-1. Cell Death Discov. 2022. PMID: 36379918 Free PMC article. - Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system.
Nguyen TTT, Tamai M, Harama D, Kagami K, Kasai S, Watanabe A, Akahane K, Goi K, Inukai T. Nguyen TTT, et al. Int J Hematol. 2022 Oct;116(4):534-543. doi: 10.1007/s12185-022-03369-x. Epub 2022 May 6. Int J Hematol. 2022. PMID: 35524023 - Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model.
Lindström HJG, Friedman R. Lindström HJG, et al. Sci Rep. 2022 Mar 25;12(1):5164. doi: 10.1038/s41598-022-09048-5. Sci Rep. 2022. PMID: 35338182 Free PMC article. - Recent advances of SIRT1 and implications in chemotherapeutics resistance in cancer.
Yousafzai NA, Jin H, Ullah M, Wang X. Yousafzai NA, et al. Am J Cancer Res. 2021 Nov 15;11(11):5233-5248. eCollection 2021. Am J Cancer Res. 2021. PMID: 34873458 Free PMC article. Review.
References
- Deininger M. W., Druker B. J. (2003) Pharmacol. Rev. 55, 401–423 - PubMed
- Gorre M. E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P. N., Sawyers C. L. (2001) Science 293, 876–880 - PubMed
- Shah N. P., Nicoll J. M., Nagar B., Gorre M. E., Paquette R. L., Kuriyan J., Sawyers C. L. (2002) Cancer Cell 2, 117–125 - PubMed
- Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., Herrmann R., Lynch K. P., Hughes T. P. (2002) Blood 99, 3472–3475 - PubMed
- Weisberg E., Manley P. W., Breitenstein W., Brüggen J., Cowan-Jacob S. W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., Kung A. L., Mestan J., Daley G. Q., Callahan L., Catley L., Cavazza C., Azam M., Mohammed A., Neuberg D., Wright R. D., Gilliland D. G., Griffin J. D. (2005) Cancer Cell 7, 129–141 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous